|
Price: $184.8400
$1.88 
1.028%
|
| Day's High:
| $185
| Week Perf:
| -0.05 %
|
| Day's Low: |
$ 181.28 |
30 Day Perf: |
8.44 % |
| Volume (M): |
104 |
52 Wk High: |
$ 280.62 |
| Volume (M$): |
$ 19,242 |
52 Wk Avg: |
$214.44 |
| Open: |
$181.60 |
52 Wk Low: |
$156.56 |
|
|
| Market Capitalization (Millions $) |
256,989 |
| Shares
Outstanding (Millions) |
1,390 |
| Employees |
4,344 |
| Revenues (TTM) (Millions $) |
2,204 |
| Net Income (TTM) (Millions $) |
-955 |
| Cash Flow (TTM) (Millions $) |
-1,120 |
| Capital Exp. (TTM) (Millions $) |
536 |
Beigene Ltd
BeiGene Ltd is a globally recognized, commercial-stage biopharmaceutical company dedicated to developing and commercializing innovative and targeted oncology therapeutics for patients across the globe. It was founded in 2010 in China by Dr. John Oyler and continues to operate with a primary focus on developing and commercializing innovative immuno-oncology medicines for patients with cancer.
Over the years, the company has expanded and become an integrated global biopharmaceutical company. It currently boasts of a comprehensive portfolio of oncology assets that includes both commercial-stage products and clinical candidates. The company aims to provide cancer therapies that are supported by extensive clinical research and innovative medicines that are tailored to meet the unique genetic and molecular characteristics of tumors.
Beigene Ltd's most successful product to date is the anti-PD-1 antibody Tislelizumab, which is approved by China's National Medical Products Administration (NMPA) for the treatment of various types of cancer. It is also in advanced clinical development for multiple cancer indications in the US and other regions across the world.
In addition to Tislelizumab, the company has an extensive pipeline on multiple late-stage clinical programs, including the Bruton tyrosine kinase (BTK) inhibitor, Zanubrutinib, an investigational RXDX-106, a small molecule selective inhibitor of mutant RET for the treatment of solid tumors, and several other candidate therapies in advanced stages of clinical development.
The company's innovative and globally recognized research and development program have positioned it to become a leader in developing clinically differentiated and unique oncology drugs. Its therapeutic approach employs targeted and precision medicine-based solutions to combat and eradicate cancer cells.
As a result of its remarkable efforts, BeiGene Ltd has entered into numerous strategic collaborations with major global pharmaceutical companies to develop innovative therapies for patients with cancer. These collaborations have not only expanded the company's global reach but also broadened its expertise and capabilities in the development of innovative oncology drugs.
Beigene Ltd is committed to applying its vast scientific expertise and resources towards making significant progress in oncology treatment for patients globally. The company boasts a truly global presence with headquarters in Beijing, China and its research center in Massachusetts, USA; and offices in Europe and other regions across the globe. With its core focus on developing and offering innovative cancer therapies that cater to the specific health needs of patients across the globe, BeiGene Ltd continues to remain a leader in the global biopharmaceutical industry.
Company Address: c/o Mourant Governance Services (Cayman) Limited Grand Cayman 0
Company Phone Number: 949-4123 Stock Exchange / Ticker: NASDAQ BGNE
| BGNE is expected to report next financial results on February 26, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Briacell Therapeutics Corp
The May to July 31, 2023 reporting season has resumed, and many companies, including those in the Major Pharmaceutical Preparations sector, have announced their financial numbers. Among these companies is Briacell Therapeutics Corp, which recently published an operating loss of $-7.705761 million for the financial fourth quarter of 2023. Additionally, Briacell Therapeutics Corp has reported a net deficit of $-14.300 million for the interval between May and July 31, 2023, which is a significant decline compared to the balanced books it maintained during the same period last year.
One noteworthy aspect is that the value of accounts receivable for Briacell Therapeutics Corp is still below the previous year's level; however, there has been some sequential progress. It is also important to mention that the company has observed a shortfall of $-20.30 million and has generated zero revenue during the financial period of 2023.
|
|
Gt Biopharma Inc
The stock market has always been a dynamic and exciting place, filled with ups and downs that keep investors on their toes. Today, we turn our attention to the Major Pharmaceutical Preparations industry and delve into the third quarter of 2023 numbers. Specifically, we examine Gt Biopharma Inc's financial report from July to September 30, 2023, which showcased an operating surplus of $3.122 million.
It's important to note that Gt Biopharma Inc has not cited any revenue yet, making the operating surplus even more impressive. As industry reporters analyze these figures, the prevailing situation of the organization becomes clearer. To truly understand the significance of the third quarter of 2023 earnings season, let's compare it with the same period in 2022.
|
|
Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.
|
|
Procyon Corporation
Based on the financial time-frame ending September 30, 2023, Procyon Corporation has experienced significant declines and challenges, leading to a bearish outlook for the company. Depleting orders have played a crucial role in the losses incurred during this period.
The revenue for Procyon Corporation fell by -0.221% to $1.17 million compared to the previous reporting season, where revenue decreased by -2.42% from $1.20 million. This downward trend indicates a constant struggle for the company to maintain a steady revenue stream. It is clear that Procyon Corporation has been facing difficulties in generating consistent income.
|
|
China Health Industries Holdings Inc
China Health Industries Holdings Inc (CHHE) recently announced its financial results for the fiscal period ending September 30, 2023. These results demonstrate the company's ability to achieve top-line growth despite industry-wide revenue reductions. Additionally, CHHE's inventories have declined, indicating potential future demand. This article will outline the facts and set the current financial results into context.
Financial Results Overview:
For the fiscal period ending September 30, 2023, CHHE reported a zero gain of $0.00 per share, compared to a loss of $0.01 per share during the same period a year ago. Sequentially, CHHE improved from a loss of $0.01 per share in the previous quarter. This indicates progress in generating profits and more favorable financial performance.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.69 $ |
| Revenues (TTM) |
1.59 $
|
| Cash Flow (TTM) |
- |
| Cash |
2.21 $
|
| Book Value |
2.71 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.69 $
|
| Revenues (TTM) |
1.59 $ |
| Cash Flow (TTM) |
- |
| Cash |
2.21 $
|
| Book Value |
2.71 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
